Compare Abbott Laboratories (ABT) vs Weibo Corp (WB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Weibo Corp — how do they compare? Abbott Laboratories trades at $95.13 (market cap $166.94B), while Weibo Corp trades at $7.66 (market cap $1.85B). The key difference: Abbott Laboratories is far larger — about 90.2× Weibo Corp's market cap, and Weibo Corp pays the higher dividend (8.16%). Which is the better fit depends on your goals.
| ABT | WB | |
|---|---|---|
Market Cap | $166.94B | $1.85B |
Sector | Health | Media |
52-Week High | $136.62 | $12.83 |
52-Week Low | $82.57 | $7.20 |
Enterprise Value | $193.69B | $1.12B |
Dividend Yield | 2.63% | 8.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Weibo (WB) trades at $7.47, up 1.49% today, with a bullish technical signal and strong fundamentals including a 25.55% net margin and 10.33% ROE. Recent quarterly earnings missed expectations, but the company maintains robust cash flow and a high dividend yield. Valuation metrics appear attractive with a P/E of 5.29 and P/B of 0.48, while analyst sentiment is mixed with 45% buy ratings.
The outlook balances deep value against competitive pressures. The stock offers significant upside if monetization improves, but faces risks from user engagement declines and rivalry with Douyin. Near-term catalysts include Q2 2026 earnings and dividend payments, though consistent EPS misses warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
